开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2024-07-18 想成为鹰的来自上海

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：尿毒症性血管钙化
经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。

49 0

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2024-01-18 ms6000000471279078 来自山东省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：皮肤性病学
经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程：
12/19/2023 Draft Created
12/19/2023 Editor Check Requested
12/19/2023 Deferred
12/21/2023 Editor Check Requested
12/21/2023 Deferred for Preferred Editing
12/21/2023 Preferred Editing Purchased
12/21/2023 In Review
12/29/2023 Reviews Complete
01/06/2024 Publication Requested
01/08/2024 Editorial Review Completed
01/09/2024 Copy Editing in Progress
01/09/2024 Copy Editing Completed
01/09/2024 Approved
01/09/2024 Published
唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了

92 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2024-06-09 ms4000000026630167 来自上海

254265

65 0

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2023-12-21 rudy37 来自江苏省

这个请问投过的大神，这个期刊是SCI吗

125 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2024-01-19 ms5000001198964976 来自广西

请问是SCI期刊吗，有影响因子

91 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2023-06-20 雨神么么哒来自天津

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：神经病
经验分享：很好中

152 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2024-01-18 ms6000000471279078 来自山东省

可恶，我自己写的评论自己都看不了，app是不是想圈钱

101 0

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2022-07-22 120f9fa7m14暂无昵称

该期刊是不是sci

234 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2021-12-03 ms9000001047126913

审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0
偏重的研究方向：胃癌化疗;副作用
经验分享：未投

227 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2215621, encodeId=fd992215621a8, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：尿毒症性血管钙化 经验分享：这个是模块化的投稿过程。刚开始参考文献一直格式审查不通过，搞了好几天才知道问题出在哪里。后续的过程就很顺利了。审稿专家的意见也比较实际，点对点修改后，就快速发表了。虽然不是SCI，但是有分数，值得投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIzZca0B375iaU8720cdTbKDYqnlZIMtRCDIZAgoUajaHDGJt2wibq8icRVYIfMW2gayFXIMm8THoyAA/132, createdBy=12881961433, createdName=想成为鹰的, createdTime=Thu Jul 18 16:37:55 CST 2024, time=2024-07-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2182451, encodeId=38492182451c7, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：皮肤性病学 经验分享：我投稿这个期刊的体验非常好。编辑反应非常迅速，一般等一天编辑就会反馈，投稿的界面也很人性化，送审也很快，审稿人三天没有完成审稿就又会给你找三个审稿人，我的审了9天，除了投稿的时候要求填的五个还是六个审稿人，一共给我找了20个，所以9天内有2个审稿人审完，你就可以自己选择终止审稿。然后审稿人的所有意见都会在你的稿件里面加亮标出来，你只用在网页上回复审稿意见、修改稿件、回复审稿人对你文章的整体意见就行，不用专门写邮件。这是我的整个过程： 12/19/2023 Draft Created 12/19/2023 Editor Check Requested 12/19/2023 Deferred 12/21/2023 Editor Check Requested 12/21/2023 Deferred for Preferred Editing 12/21/2023 Preferred Editing Purchased 12/21/2023 In Review 12/29/2023 Reviews Complete 01/06/2024 Publication Requested 01/08/2024 Editorial Review Completed 01/09/2024 Copy Editing in Progress 01/09/2024 Copy Editing Completed 01/09/2024 Approved 01/09/2024 Published 唯一的缺点就是它要首选编辑费300美金（具体多少钱根据文章格式语言之类的水平定），交完之后当天就给我送审了，我都不知道他给我改了哪儿，可能是为了挣钱吧。总之非常快，快得我觉得我这是不是还要再改改就过了，而且我已经算慢的了（我返修花了好几天）。还有个缺点就是这个不是sci，而我只有发sci才能毕业。但是我的这篇文章已经被拒了5次了，能发我就很感动了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:28:57 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2209112, encodeId=743c2209112f6, content=254265, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffb9339109, createdName=ms4000000026630167, createdTime=Sun Jun 09 17:15:42 CST 2024, time=2024-06-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2176248, encodeId=135b21e624848, content=这个请问投过的大神，这个期刊是SCI吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be1c1714148, createdName=rudy37, createdTime=Thu Dec 21 09:59:00 CST 2023, time=2023-12-21, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2182547, encodeId=aa1c218254e8c, content=请问是SCI期刊吗，有影响因子, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b85726071, createdName=ms5000001198964976, createdTime=Fri Jan 19 01:43:11 CST 2024, time=2024-01-19, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2143986, encodeId=a618214398624, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：神经病 经验分享：很好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230521/dc12840edd284230b738aa9f46932fd6/6ca1530338e14459a8c8f010ce0f63b8.jpg, createdBy=11b51957556, createdName=雨神么么哒, createdTime=Tue Jun 20 23:17:11 CST 2023, time=2023-06-20, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2182452, encodeId=500b218245224, content=可恶，我自己写的评论自己都看不了，app是不是想圈钱, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9d8852950, createdName=ms6000000471279078, createdTime=Thu Jan 18 16:30:13 CST 2024, time=2024-01-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233954, encodeId=cedd1233954c7, content=该期刊是不是sci, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73412220233, createdName=120f9fa7m14暂无昵称, createdTime=Fri Jul 22 05:23:00 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076437, encodeId=23d510e64372b, content=审稿速度:1.0 | 投稿命中率:95.0 | 审稿费用:50.0 | 版面费用:300.0 偏重的研究方向：胃癌化疗;副作用 经验分享：未投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07f46161597, createdName=ms9000001047126913, createdTime=Fri Dec 03 07:16:49 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121703, encodeId=b4632121e0314, content=投稿还需要找6个评审人才能投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc888604681, createdName=ms1000000276062001, createdTime=Sat Mar 25 00:51:46 CST 2023, time=2023-03-25, status=1, ipAttribution=)]

2023-03-25 ms1000000276062001

投稿还需要找6个评审人才能投吗？

155 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务